Gorlin Syndrome (Nevoid Basal Cell Carcinoma Syndrome)

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Gorlin = PTCH1 or SUFU (SHH pathway). The gene sets the medulloblastoma risk: PTCH1 under 2%; SUFU up to 20 times higher. Median age at medulloblastoma in SUFU carriers is 1.5 years .
  • Screen SUFU carriers with brain MRI from birth to 5. PTCH1 carriers do not need medulloblastoma screening .
  • Infant desmoplastic or nodular SHH medulloblastoma: test the germline. SUFU children often lack classic Gorlin features but have macrocrania .
  • Avoid radiotherapy. Radiation-sparing chemotherapy gives excellent survival. Radiation brings second malignancies , including basal cell carcinomas in the field (see caveats).
  • SUFU medulloblastoma relapses locally more often .

Gorlin syndrome (nevoid basal cell carcinoma syndrome, or basal cell nevus syndrome) is a cancer-predisposition syndrome. It is caused by a germline pathogenic variant in a Sonic Hedgehog (SHH) pathway gene, PTCH1 or SUFU .

Its tumors fall into two groups :

For the neurosurgeon, two decisions depend on the gene:

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:gorlin_syndrome:a3698c4945b26042© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Child with macrocephaly and frontal bossing, palmar pits, a panoramic jaw film with odontogenic keratocysts, a bifid rib and lamellar falx calcification; a nodular desmoplastic SHH medulloblastoma in an infant posterior fossa; the SHH pathway with PTCH1 and SUFU and their medulloblastoma risks; and basal cell carcinomas in a radiation field(A) PHENOTYPE AND IMAGING CLUESmacrocephaly,frontal bossingpalmar pits(also plantar)odontogenic keratocystsbifid riblamellar falx calcification (CT)layered falx(B) DESMOPLASTIC / NODULAR SHH MEDULLOBLASTOMA (INFANT)grape-like nodules(MBEN pattern), vermisand hemispherefourth ventricleexcellent survival withradiation-sparing chemotherapy(Gorlin cohort)(C) SHH PATHWAY AND MEDULLOBLASTOMA RISK BY GENESHHPTCH1SMOSUFUGLItarget genes: proliferationof granule-neuron precursorsPTCH1 restrains SMO; SUFU restrains GLI. Germline loss of either (Gorlin) releases the pathway.PTCH1under 2% medulloblastoma riskSUFUup to ~20x higherMRI birth to 5 y for SUFU carriers(D) AVOID RADIOTHERAPY: BASAL CELL CARCINOMAS IN THE FIELDcraniospinal radiation field(dashed)multiple pearly basal cellcarcinomas years laterjaw keratocysts (PTCH1): dental examfrom 2 y, orthopantogram from ~8 y
Gorlin syndrome. (a) Child with macrocephaly and frontal bossing; palmar pits; jaw odontogenic keratocysts on panoramic radiograph; bifid ribs; lamellar calcification of the falx. (b) Midsagittal posterior fossa: a nodular, desmoplastic SHH medulloblastoma in the cerebellar hemisphere/vermis of an infant. (c) SHH pathway: PTCH1 restrains SMO, SUFU restrains GLI; loss of either activates GLI targets. Gene-specific risk: SUFU carriers far more likely to develop infant medulloblastoma than PTCH1 carriers. (d) Radiation field with later multiple basal cell carcinomas. Not to scale.

Genetics: why the gene matters

Medulloblastoma in Gorlin syndrome

Surveillance (SIOPE 2021 recommendations)

Recognizing Gorlin syndrome

Related topics

References

  1. Guerrini-Rousseau L, Smith MJ, Kratz CP, et al. Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG). Fam Cancer 2021;20(4):317–325. doi:10.1007/s10689-021-00247-z. PMID 33860896. verified
  2. Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014;32(36):4155–4161. doi:10.1200/JCO.2014.58.2569. PMID 25403219. verified
  3. Bree AF, Shah MR; BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet A 2011;155A(9):2091–2097. doi:10.1002/ajmg.a.34128. PMID 21834049. verified
  4. Guerrini-Rousseau L, Masliah-Planchon J, Waszak SM, et al. Cancer risk and tumour spectrum in 172 patients with a germline SUFU pathogenic variation: a collaborative study of the SIOPE Host Genome Working Group. J Med Genet 2022;59(11):1123–1132. doi:10.1136/jmedgenet-2021-108385. PMID 35768194. verified
  5. Guerrini-Rousseau L, Dufour C, Varlet P, et al. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro Oncol 2018;20(8):1122–1132. doi:10.1093/neuonc/nox228. PMID 29186568. verified
  6. Kloth K, Obrecht D, Sturm D, et al. Defining the spectrum, treatment and outcome of patients with genetically confirmed Gorlin syndrome from the HIT-MED cohort. Front Oncol 2021;11:756025. doi:10.3389/fonc.2021.756025. PMID 34888241. verified

Verification (2026-11-17):

Caveats: